Skip NavigationSkip to Content

The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis

  1. Author:
    Qu, W.
    Liu, J.
    Fuquay, R.
    Saavedra, J. E.
    Keefer, L. K.
    Waalkes, M. P.
  2. Author Address

    NCI, Natl Inst Environm Hlth Sci, Comparat Carcinogenesis Lab, Inorgan Carcinogenet Sect, Res Triangle Pk, NC 27709 USA. NCI, SAIC Frederick, Basic Res Program, Frederick, MD 21701 USA. NCI, Comparat Carcinogenesis Lab, Chem Sect, Frederick, MD 21701 USA.;Waalkes, MP, NCI, Natl Inst Environm Hlth Sci, Comparat Carcinogenesis Lab, Inorgan Carcinogenet Sect, POB 12233,Mail Drop F0-09,111 Alexander Dr, Res Triangle Pk, NC 27709 USA.;waalkes@niehs.nih.gov
    1. Year: 2007
    2. Date: Oct
  1. Journal: Cancer Letters
    1. 256
    2. 2
    3. Pages: 238-245
  2. Type of Article: Article
  3. ISSN: 0304-3835
  1. Abstract:

    Arsenite is an important cancer chemotherapeutic. The liver is a major target tissue of arsenic toxicity and hepatotoxicity may limit its chemotherapeutic efficacy. O-2 -vinyl 1-(pyrrolidin-1-yl)diazen-l-ium-1,2-diolate (V-PYRRO/NO) is a liver-selective nitric oxide (NO)-producing prodrug metabolized by hepatic P450 enzymes to release NO locally. V-PYRRO/NO protects against various organic or inorganic hepatotoxicants but any role in arsenic hepatotoxicity is undefined. Thus, we studied the effects of V-PYRRO/NO (0-1000 mu M) pretreatment on inorganic arsenic-induced toxicity in cultured rat liver (TRL 1215) cells. These cells metabolized the prodrug to release NO, producing extracellular nitrite levels to 41.7-fold above control levels (7.50 +/- 0.38 mu M) after 24 h V-PYRRO/NO (1000 mu M) exposure. The effect of pretreatment with V-PYRRO/NO (24 h) on the cytolethality of arsenic (as NaAsO2,) exposure (24 h) was assessed. Arsenic was markedly less toxic in V-PYRRO/NO pretreated cells (LC50 = 30.3 mu) compared to control (LC50 20.1 mu M) and the increases in LC50 showed a direct relationship to the level of NO produced (measured as nitrite). Consistent with the cytolethality data, V-PYRRO/NO pretreatment markedly reduced arsenic-induced apoptosis as assessed by DNA fragmentation. Activation of the c-Jun N-terminal kinase (JNK) pathway can be critical to apoptosis and pretreatment with VPYRRO/NO suppressed arsenic-induced JNK activation. V-PYRRO/NO pretreatment modestly increased metallothionein (MT), a metal-binding protein, but greatly enhanced arsenic induction of MT. Thus, V-PYRRO/NO pretreatment directly mitigates arsenic toxicity in cultured liver cells, reducing cytolethality, apoptosis and related JNK pathway activation, apparently through generation of NO. The role of NO in reducing the hepatotoxicity of arsenical chemotherapeutics in vivo deserves additional study. Published by Elsevier Ireland Ltd.

    See More

External Sources

  1. DOI: 10.1016/j.canlet.2007.06.009
  2. WOS: 000250327100009

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel